Idasanutlin as a new treatment option in improving the therapeutic odyssey of relapsed/refractory AML.

Corbali M., Eskazan A. E.

Future oncology (London, England), cilt.16, 2020 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Editöre Mektup
  • Cilt numarası: 16
  • Basım Tarihi: 2020
  • Doi Numarası: 10.2217/fon-2020-0218
  • Dergi Adı: Future oncology (London, England)
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
  • Anahtar Kelimeler: acute myeloid leukemia, AML, idasanutlin, MDM2 inhibitor, relapsed or refractory, TP53, ACUTE MYELOID-LEUKEMIA, PLUS CYTARABINE
  • İstanbul Üniversitesi-Cerrahpaşa Adresli: Evet